Cotemporary DES paired with FFR guidance and modern medical therapy may be what narrowed the gap, William Fearon says.

The prothrombin complex concentrate costs more than plasma, but may pay dividends by way of fewer adverse events.

The SINGLE SHOT CHAMPION study increases momentum for PFA as a first-line option for pulmonary vein isolation, say experts.

Despite the randomized trial showing a difference in outcomes, more data are needed before changing practice, says one expert ...

Experts are dismayed, disappointed, and confused, but many say this isn’t the end of cerebral embolic protection for TAVI.

Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...

The follow-up brought little surprise, with investigators pleased the risk of death/disabling stroke remained on par with ...

Findings from the first 500 patients treated with the Trilogy system met noninferiority for both safety and efficacy.

There are worries about delayed complications, but many places won’t get paid if AF patients don’t spend the night in ...

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

While the exact mechanism is unknown, the data suggest a multitude of benefits independent of large weight loss.

On top of noninferior efficacy, the trial showed patients had less bleeding with 2.5 mg vs 5.0 mg twice daily over 12 months.